1. Origa R, Galanello R, Perseu L, Tavazzi D, Domenica Cappellini M,Terenzani L, Forni GL, Quarta G, Boetti T, Piga A.
Cholelithiasis in thalassemia major.
Eur J Haematol. 2009; 82: 22-5. IF 2,163

2. Melis MA, Cau M, Congiu R, Sole G, Barella S, Cao A, Westerman M, Cazzola M, Galanello R.
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.
Haematologica. 2008; 93:1473-9. IF 5,516

3. Origa R, Barella S, Argiolas GM, Bina P, Agus A, Galanello R.
No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia.
Haematologica. 2008; 93:1095-6. IF 5,516

4. Mosca A, Paleari R, Galanello R, Sollaino C, Perseu L, Demartis FR, Passarello C, Giambona A, Maggio A; IFCC Working Group on Standardization of HbA2.
New analytical tools and epidemiological data for the identification of HbA2 borderline subjects in the screening for beta-thalassemia.
Bioelectrochemistry. 2008; 73: 137-40. IF 2,992

5. Origa R, Satta S, Matta G, Galanello R.
Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major.
Br J Haematol. 2008; 142:143-5. IF 4,490

6. Pession A, Dama E, Rondelli R, Magnani C, De Rosa M, Locatelli F, Fagioli F, Haupt R, Jankovic M, Terracini B, Merletti F, Pastore G; Italian Association of Paediatric Haematology and Oncology.
Survival of children with cancer in Italy, 1989-98. A report from the hospital based registry of the Italian Association of Paediatric Haematology and Oncology (AIEOP).
Eur J Cancer. 2008; 44:1282-9. IF 4,454

7. Sadelain M, Boulad F, Lisowki L, Moi P, Riviere I.
Stem cell engineering for the treatment of severe Hemoglobinopathies.
Curr Mol Med. 2008; 8:690-7. IF 4,624

8. Moi P, Sadelain M.
Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells.
Haematologica. 2008; 93: 325-30. IF 5,516

9. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, Busonero F, Maschio A, Albai G, Piras MG, Sestu N, Lai S, Dei M, Mulas A, Crisponi L, Naitza S, Asunis I, Deiana M, Nagaraja R, Perseu L, Satta S, Cipollina MD, Sollaino C, Moi P, Hirschhorn JN, Orkin SH, Abecasis GR, Schlessinger D, Cao A.
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia.
Proc Natl Acad Sci U S A. 2008; 105:1620-5. IF 9,598

10. Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S.
Italian Society of Hematology practice guidelines for the management of iron
overload in thalassemia major and related disorders.
Haematologica. 2008; 93: 741-52. IF 5,516

11. Wood JC, Origa R, Agus A, Matta G, Coates TD, Galanello R.
Onset of cardiac iron loading in pediatric patients with thalassemia major.
Haematologica. 2008; 93: 917-20. IF 5,516

12. Cao A, Congiu R, Sollaino MC, Desogus MF, Demartis FR, Loi D, Cau M, Galanello R.
Thalassaemia and glucose-6-phosphate dehydrogenase screening in 13- to
14-year-old students of the Sardinian population: preliminary findings.
Community Genet. 2008;11: 121-8. IF 1,197

13. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ.
Combined chelation therapy in thalassemia major for the treatment of severe
myocardial siderosis with left ventricular dysfunction.
J Cardiovasc Magn Reson. 2008; Feb 25;10-12. IF 1,870

14. Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Rivière GJ, Balez S, Alberti D, Séchaud R.
Effect of food, type of food, and time of food intake on deferasirox
bioavailability: recommendations for an optimal deferasirox administration
regimen.
J Clin Pharmacol. 2008; 48: 428-35. IF 2,993

15. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD,
Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M,
Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C.
Relative response of patients with myelodysplastic syndromes and other
transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
Eur J Haematol. 2008; 80:168-76. IF 2,163

16. Marcialis MA, Faà V, Fanos V, Puddu M, Pintus MC, Cao A, Rosatelli MC.
Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis.
Pediatr Nephrol. 2008; 23: 2267-71. IF 1,936

17. Meloni A, Incani F, Corda D, Cao A, Rosatelli MC.
Role of PHD fingers and COOH-terminal 30 amino acids in AIRE transactivation activity.
Mol Immunol. 2008; 45: 805-9. IF 3,742

18. Nucaro AL, Melis P, Casini MR, Rossino R, Cau M, Melis MA, Loche S.
Turner syndrome mosaicism: an unusual case with a de novo large dicentric marker chromosome: mos 45,X/46,X, ter rea(X;X)(p22.3;p22.3).
J Appl Genet. 2008; 49:301-3. IF 0,967

19. Falbo V, Floridia G, Tosto F, Censi F, Salvatore M, Ravani A, Ferlini A, Melis MA, Grasso M, Bricarelli FD, Taruscio D.
The Italian External Quality Assessment scheme for fragile x syndrome: the results of a 5-year survey.
Genet Test. 2008; 12: 279-88. IF 1,218

20. McCrea HJ, Paradise S, Tomasini L, Addis M, Melis MA, De Matteis MA, De Camilli P.
All known patient mutations in the ASH-RhoGAP domains of OCRL affect targeting and APPL1 binding.
Biochem Biophys Res Commun. 2008; 369:493-9. IF 2,749

21. Terracciano A, Sanna S, Uda M, Deiana B, Usala G, Busonero F, Maschio A, Scally M, Patriciu N, Chen WM, Distel MA, Slagboom EP, Boomsma DI, Villafuerte S, Sliwerska E, Burmeister M, Amin N, Janssens AC, van Duijn CM, Schlessinger D, Abecasis GR, Costa PT Jr.
Genome-wide association scan for five major dimensions of personality
Mol Psychiatry. 2008; Oct 28 IF 10,900

22. Arnaud-Lopez L, Usala G, Ceresini G, Mitchell BD, Pilia MG, Piras MG, Sestu N, Maschio A, Busonero F, Albai G, Dei M, Lai S, Mulas A, Crisponi L, Tanaka T, Bandinelli S, Guralnik JM, Loi A, Balaci L, Sole G, Prinzis A, Mariotti S, Shuldiner AR, Cao A, Schlessinger D, Uda M, Abecasis GR, Nagaraja R, Sanna S, Naitza S.
Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function
Am J Hum Genet. 2008; 82:1270-80. IF 11,092

23. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda
M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR.
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Nat Genet. 2008; 40:161-9. IF 30,693

24. Okur I, Tumer L, Crisponi L, Eminoglu FT, Chiappe F, Cinaz P, Yenicesu I, Hasanoglu A.
Crisponi syndrome: a new case with additional features and new mutation in CRLF1.
Am J Med Genet A. 2008; 146:3237-9. IF 2.479

25. Pusceddu V, Frau B, Guerzoni D, Catani G, Murgia M, Murru M, Ionta MT, Massidda B.
Undescribed Case of Necrotic Ulcerative Amyopathic Dermatomyositis in Bone Metastatic Breast Cancer
Breast J. 2008; 14:591-2. IF 1,739

26. Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, Maiorino L, Palmeri S, Cannone M, Condemi G; on behalf of the Southern Italy Cooperative Oncology Group.
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
J Cancer Res Clin Oncol. 2009 Feb;135:217-226 (accept. Aug 22). IF 2,366

27. De Conno F, Ripamonti C, Fagnoni E, Brunelli C, Luzzani M, Maltoni M, Arcuri E, Bertetto O Massidda B; MERITO Study Group
The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain.
Palliat Med. 2008; 22: 214-21. IF 1,652

28. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R.
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
J Natl Cancer Inst. 2008; 100:388-98. IF 15,678

29. G. Viale, a Giobbie-Hurder, MM Regan, Al S. Coates… B.Massidda, MT. Ionta, MC Deidda,… and Aron Goldhirsch
Prognostic and predictive value of centrally reviewed KI-67 L.I. in post
Menopausal women with endocrine-responsive breast cancer : Results…
Journal of Clinical Oncology, 2008; 26:5569-75.IF 15,489

30. Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G,
Maiorino L, Palmeri S, Cannone M, Condemi G; on behalf of the Southern
Italy Cooperative Oncology Group.
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus
Oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer
Patients: results of the Southern Italy Cooperative Oncology study 0401.
J Cancer Res Clin Oncol. 2009; Feb; 135(2): 217-226. IF.2,366

31. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer : supplementary results from the BIG 1-98 randomized trial.
Collaborative and International Breast Cancer Study Groups
Lancet Oncology, 2008; ;9: 23-28. IF12,0

32. V. Pusceddu, MT Ionta, B.Massidda
Undescribed case of necrotic ulcerative amyopathic dermatomyositis in bone
Metastatic breast case.
The Breast Journal, 2008, 14: 591-2. IF.1,740

33. Mercadante S., Roila F., Massidda B., Capra D., Casilini
Prevalence and treatment of cancer pain in Italian oncological wards centres:
A cross-sectional survey.
Supportive Care in Cancer, 2008, on line 14 may. IF 1,60

34. De Conno F., Ripamonti C., Massidda B.,
The MERITO Study: a multicentre trial of the analgesic effect and tolerability
Of normal release oral morphine durin titration phase in pts with cancer pain.
Palliative Medicine, 2008, 22: 214-221. IF 1,861

35. Comella P., Gambardella A., Massidda B., , Costanzo R.
Comparison of the safethy and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic NSCLC. A rectrospective analysis.
Crit. Rev. Oncol. Ematol., 2008; 65: 164-171. IF 4,632

36. Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B,Farris A, Leo S, Roselli M, Sandomenico C, Mancerella S, Palmeri S, Greco E, Franco L.
Three-drug regimen including oxaliplatin, irinotecan, and fluorouracil/folinic acid
In advanced gastric cancer: a multicenter phase II trial of the SICOG.
Cancer Chemother Pharmacol, 2008 (accepted).

37. Ionta MT, Frau B, Murgia M, Pusceddu V, Deidda MC, Murru M, Barca M,
Guerzoni D, Palmeri S, Minerba L, Massidda B, Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (<pCR) after primary chemotherapy:What are their chances of survival?
J. Cancere Research and Clin Oncol, , 2008 submitted

IMPACT FACTOR: 2008 191,023 (+ 78%)
IMPACT FACTOR: 2007 107,729